Searched for
ELEPSIA
USFDA rules against Sun Pharma Advanced Research Co's appeal regarding cancer drug applicationThe Office of New Drugs (OND) of the US Food and Drug Administration (FDA) has denied the company's appeal of the Complete Response Letter ...- SPARC plunges 10% as USFDA rejects application for cancer drug TaclantisThe company informed this to the exchanges after market hours of Tuesday.
- Sun Pharma arm gets USFDA nod for epilepsy drugThe subsidiary concerned had in-licensed Elepsia XR from Sun Pharma Advanced Research Company (SPARC) in July 2016.
- Sun Pharma climbs 2% on USFDA approvalThe drug in question is CEQUA (cyclosporine ophthalmic solution) 0.09 per cent.
- Sun Pharma rises with R&D and bets on specialty drugsSun Pharma- India's largest drug maker - is vying for its share in the US$9 billion market through a drug, Ilumya, that treats moderate-to-...
- Sun Pharma hits 44-month low, down 24% in 7 sessions; what experts sayThe stock fell 12.84 per cent to hit a 44-month low of Rs 495.55 amid weak fourth quarter results.
- Mapping the market: Data war hits telcos hard; royalty burden spooks OIL, ONGCAll in all, it was a stock-specific session where Sensex fell 90 points to 27,746, while Nifty50 barely managed to hold above the 8,500 mar...
- SPARC, Sun Pharma climb on licensing agreementThe deal will make the company eligible for certain additional milestone payments and defined royalties linked to any future sales of ELEPS...
- GST delay, HUL Q1 spook market; Sensex declines 90 points, Nifty50 holds above 8,500Shares of Bharti Airtel and Idea Cellular declined after the two companies decided to lower data tariff. Airtel slipped 3.86 per cent while...
- SPARC and Sun Pharma ink licensing pact for epilepsy drug"As per the agreement, SPARC will license Elepsia XRTM (Levetiracetam Extended Release tablets) to a wholly-owned subsidiary of Sun Pharma ...
- Expect delay in start of royalty from 2 new drugs: SPARCSun Pharma Advanced Research Company (SPARC) expects further delay in start of royalty income from its two new drug applications, including...
- USFDA nod to Sun Pharma for Gleevec may add $250-450 million to sales, boost short-term prospectsSurajitPal, analyst at Prabhudas Lilladher factored in the best-case scenario putting Sun Pharma’s sales from Gleevec at $450 million.
- SPARC, Sun Pharma slide as USFDA rescinds approval to drugShares of Sun Pharma Advanced Research Company today fell by almost 3 per cent as the US health regulator has revoked its earlier approval ...
- SPARC, Sun Pharma drop on USFDA revocation of approvalShares of SPARC closed 2.62 per cent lower at Rs 375.80 after hitting the day's low of Rs 368.50 on the exchange. Parent Sum Pharma ended 3...
- Sensex slips 200 points, Nifty tests 7,800; PMC, Tata Motors down 5%The S&P BSE Sensex traded 200 points lower on Monday tracking weakness in European markets and mixed closing in other Asian markets.
- Ten stocks in focus in Monday's tradeIndian markets are expected to trade in a range. Here is a list of ten stocks which are likely to remain in focus today.
- Sun Pharma Advanced Research Company shares surge 15 per cent; m-cap up by Rs 1,685 croreStocks of Sun Pharma Advanced Research Company Ltd surged 15 per cent today after the company received approval from the US health regulato...
- SPARC shares settle with 5 per cent gain; market capitalisation up by Rs 440 croreELEPSIA XR is indicated for adjunctive therapy in the treatment of partial onset seizures in patients of 12 years of age and older with epi...
- SPARC gets USFDA nod for its anti-epileptic drug ELEPSIA XR"Approval of ELEPSIA XRTM as 1,000 mg and 1,500 mg once a day tablets will be very useful for these patients and physicians."
Load More
